ClinicalTrials.gg
CompletedNCT00528411Updated Jan 13, 2012Results posted

A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin

A Phase 2 interventional study of Ticagrelor Tablets and Clopidogrel (over encapsulated) capsule in Coronary Artery Disease, sponsored by AstraZeneca. Completed at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-01-13.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
123
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 78 studies testing ticagrelor in Coronary Artery Disease — 5 open to participants now, 5 under way, 2 of them phase 3. Ticagrelor · Coronary Artery Disease.

Enrollment
26th of 78
123 · median 80
Started
2007
the only one that year
Phase 2
7 of 78
none open now
Registered
2nd of 78
by date
Lead sponsor
9 of 78
AstraZeneca

Among the 78 studies testing ticagrelor in Coronary Artery Disease, this one is the 26th largest by enrollment, is the only one that started in 2007, is one of 7 in phase 2, and was the 2nd registered.

Coronary Artery Disease

4,863 studies on the registry are indexed under Coronary Artery Disease; 893 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

5 of the 78 studies testing ticagrelor in Coronary Artery Disease are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ticagrelor

Ticagrelor: first FDA approval 2011 (BRILINTA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 589 Coronary Artery Disease studies recruiting now, 403 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 38 take children under 18; 48 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies testing ticagrelor in Coronary Artery Disease, or all of them as a file.
02

Study summary

The purpose of this study is to see how Ticagrelor, a new oral reversible anti-platelet medication, affects platelets. Anti-platelet agents are medications that block the formation of blood clots by preventing the clumping of platelets. Blood clots prevent us from bleeding, but when they form inside the arteries their formation is linked to a risk of medical problems such as heart attack and stroke. This study investigated how long it takes for Ticagrelor to begin working and how long it takes for it to stop working after the last dose of drug. Ticagrelor will be compared to clopidogrel, an established anti-platelet treatment for preventing blood clots, and placebo plus Aspirin.

03

Conditions studied

  • Coronary Artery Disease

Keywords

  • Coronary artery disease
  • CAD
  • heart attack
  • stable angina
  • Stable coronary artery disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented stable Coronary Artery Disease (stable angina, previous MI history, previous history of revascularization);
  • Females of child bearing potential must have a negative pregnancy test prior to receiving study drug and be willing to use a hormonal in addition to double barrier contraception

Exclusion criteria

Exclusion Criteria:

  • History of Acute Coronary Syndromes within 12 months of screening or need for revascularization (angioplasty or Coronary Artery Bypass Graft (CABG))
  • History of liver or kidney disease
  • Have increased bleeding risk, eg, recent gastrointestinal bleed, uncontrolled high blood pressure, low count, recent major trauma
  • History of intolerance or allergy to Aspirin or clopidogrel
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
123 participants (actual)

Study arms

  • Active comparator
    1

    Aspirin + Placebo

    Drug: Aspirin Tablets

  • Active comparator
    2

    Aspirin + clopidogrel

    Drug: Clopidogrel (over encapsulated) capsule · Drug: Aspirin Tablets

  • Experimental
    3

    Aspirin + Ticagrelor

    Drug: Ticagrelor Tablets · Drug: Aspirin Tablets

Interventions

  • Oral, 90 mg; 180 mg loading dose followed by 90 mg twice daily (BD)

  • Oral 75 mg; 600 mg loading dose followed by 75 mg once daily (ODD)

    Also known as: Plavix, Clopidogrel Bisulfate

  • Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study.

    Also known as: ASA

06

What researchers measure

Primary outcomes

  1. Final Extent Inhibition of Platelet Aggregation (IPA) Induced by 20 µM Adenosine Diphosphate (ADP) at 2 Hours After First Dose

    IPA(%)=(PAb-PAt)/PAb\*100.The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

    Time frame: At 2 hours after first dose of study drug

  2. Slope of Extent IPA Offset Curve 4 to 72 Hours After Last Dose of Study Drug

    IPA(%)=(PAb-PAt)/PAb\*100.The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. The unit for the slope of IPA curve is percent/hour.

    Time frame: 4 to 72 Hours after last dose of study drug

Secondary outcomes

  1. Final Extent IPA Induced by 20 µM ADP at 0.5 Hours After First Dose

    IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

    Time frame: 0.5 hours after first dose

  2. Final Extent IPA Induced by 20 µM ADP at 1 Hour After First Dose

    IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

    Time frame: 1 hour after first dose

  3. Final Extent IPA Induced by 20 µM ADP at 4 Hours After First Dose

    IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

    Time frame: 4 hours after first dose

  4. Final Extent IPA Induced by 20 µM ADP at 8 Hours After First Dose

    IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

    Time frame: 8 hours after first dose

  5. Final Extent IPA Induced by 20 µM ADP at 24 Hours After First Dose

    IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

    Time frame: 24 hours after first dose

  6. Final Extent IPA Induced by 20 µM ADP at 0 Hour Before Last Dose

    IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

    Time frame: 0 hour before last dose

  7. Final Extent IPA Induced by 20 µM ADP at 2 Hours After Last Dose

    IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

    Time frame: 2 hours after last dose

  8. Final Extent IPA Induced by 20 µM ADP at 4 Hours After Last Dose

    IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

    Time frame: 4 hours after last dose

  9. Final Extent IPA Induced by 20 µM ADP at 8 Hours After Last Dose

    IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

    Time frame: 8 hours after last dose

  10. Final Extent IPA Induced by 20 µM ADP at 24 Hours After Last Dose

    IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

    Time frame: 24 hours after last dose

  11. Final Extent IPA Induced by 20 µM ADP at 48 Hours After Last Dose

    IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

    Time frame: 48 hours after last dose

  12. Final Extent IPA Induced by 20 µM ADP at 72 Hours After Last Dose

    IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

    Time frame: 72 hours after last dose

  13. Final Extent IPA Induced by 20 µM ADP at 120 Hours - Day 5 After Last Dose

    IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

    Time frame: 120 hours - Day 5 after last dose

  14. Final Extent IPA Induced by 20 µM ADP at 168 Hours - Day 7 After Last Dose

    IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference of baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

    Time frame: 168 hours - Day 7 after last dose

  15. Final Extent IPA Induced by 20 µM ADP at 240 Hours - Day 10 After Last Dose

    IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

    Time frame: 240 hours - Day 10 after last dose

  16. Cardiopulmonary Parameters at Baseline: Forced Expiratory Volume in 1 Second (FEV1)

    FEV1 is measured by Spirometry, the unit is Liter.

    Time frame: Baseline

  17. Cardiopulmonary Parameters at Post 6-week Treatment: FEV1

    FEV1 is measured by Spirometry, the unit is Liter.

    Time frame: 6-week post treatment

  18. Cardiopulmonary Parameters at Baseline: Forced Vital Capacity (FVC)

    FVC is measured by Spirometry, the unit is Liter.

    Time frame: Baseline

  19. Cardiopulmonary Parameters at Post 6-week Treatment: FVC

    FVC is measured by Spirometry, the unit is Liter.

    Time frame: 6-week post treatment

  20. Cardiopulmonary Parameters at Baseline: Ratio of Forced Expiratory Volume in 1 Second Over Forced Vital Capacity (FEV1/FVC Ratio)

    FEV1/FVC Ratio is measured by Spirometry, the unit is Ratio.

    Time frame: Baseline

  21. Cardiopulmonary Parameters at Post 6-week Treatment: FEV1/FVC Ratio

    FEV1/FVC Ratio is measured by Spirometry, the unit is Ratio.

    Time frame: 6-week post treatment

  22. Cardiopulmonary Parameters at Baseline: Mean Forced Expiratory Flow Between 25% and 75% of the FVC (FEF25-75)

    FEF25-75 is measured by Spirometry, the unit is Liter/Second.

    Time frame: Baseline

  23. Cardiopulmonary Parameters Post 6-week Treatment: FEF25-75

    FEF25-75 is measured by Spirometry, the unit is Liter/Second.

    Time frame: 6-week post treatment

  24. Cardiopulmonary Parameters at Baseline: Functional Residual Capacity (FRC)

    FRC is measured by Body Box Plethysmography, the unit is Liter.

    Time frame: Baseline

  25. Cardiopulmonary Parameters Post 6-week Treatment: FRC

    FRC is measured by Body Box Plethysmography, the unit is Liter.

    Time frame: 6-week post treatment

  26. Cardiopulmonary Parameters at Baseline: Total Lung Capacity (TLC)

    TLC is measured by Body Box Plethysmography, the unit is Liter.

    Time frame: Baseline

  27. Cardiopulmonary Parameters Post 6-week Treatment: TLC

    TLC is measured by Body Box Plethysmography, the unit is Liter.

    Time frame: 6-week post treatment

  28. Cardiopulmonary Parameters at Baseline: Residual Volume (RV)

    RV is measured by Body Box Plethysmography, the unit is Liter.

    Time frame: Baseline

  29. Cardiopulmonary Parameters Post 6-week Treatment: RV

    RV is measured by Body Box Plethysmography, the unit is Liter.

    Time frame: 6-week post treatment

  30. Cardiopulmonary Parameters at Baseline: Minute Ventilation (VE)

    VE is measured by Spirometry and Body Box Plethysmography, the unit is Liter/Minute

    Time frame: Baseline

  31. Cardiopulmonary Parameters Post 6-week Treatment: VE

    VE is measured by Spirometry and Body Box Plethysmography, the unit is Liter/Minute

    Time frame: 6-week post treatment

  32. Cardiopulmonary Parameters at Baseline: Respiratory Rate (RR)

    RR is measured by Spirometry and Body Box Plethysmography, the unit is Breaths/Minute.

    Time frame: Baseline

  33. Cardiopulmonary Parameters Post 6-week Treatment: RR

    RR is measured by Spirometry and Body Box Plethysmography, the unit is Breaths/Minute.

    Time frame: 6-week post treatment

  34. Cardiopulmonary Parameters at Baseline: Tidal Volume (VT)

    VT is measured by Body Box Plethysmography, the unit is Liter/Minute.

    Time frame: Baseline

  35. Cardiopulmonary Parameters Post 6-week Treatment: VT

    VT is measured by Body Box Plethysmography, the unit is Liter/Minute.

    Time frame: 6-week post treatment

  36. Cardiopulmonary Parameters at Baseline: Single Breath Diffusing Capacity for the Lungs Using Carbon Monoxide (DLCOSB)

    DLCOSB is measured by Body Box Plethysmography, the unit is Percent.

    Time frame: Baseline

  37. Cardiopulmonary Parameters Post 6-week Treatment: DLCOSB

    DLCOSB is measured by Body Box Plethysmography, the unit is Percent.

    Time frame: 6-week post treatment

  38. Cardiopulmonary Parameters at Baseline: Ejection Fraction (EF)

    EF is measured by Echocardiogram, the unit is Percent. The ejection fraction is defined by: (LV diastolic volume - LV systolic volume)/LV diastolic volume. The unit % is the percentage change of left ventricular diastolic versus systolic volume relative to the diastolic volume. LV is the left ventricle.

    Time frame: Baseline

  39. Cardiopulmonary Parameters Post 6-week Treatment: EF

    EF is measured by Echocardiogram, the unit is Percent. The ejection fraction is defined by: (LV diastolic volume - LV systolic volume)/LV diastolic volume. The unit % is the percentage change of left ventricular diastolic versus systolic volume relative to the diastolic volume. LV is the left ventricle.

    Time frame: 6-week post treatment

  40. Cardiopulmonary Parameters at Baseline: N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)

    NT-proBNP is measured by clinical lab, the unit is pg/mL.

    Time frame: Baseline

  41. Cardiopulmonary Parameters Post 6-week Treatment: NT-proBNP

    NT-proBNP is measured by clinical lab, the unit is pg/mL.

    Time frame: 6-week post treatment

  42. Cardiopulmonary Parameters at Baseline: Blood Oxygen Saturation Measured by Pulse Oximetry (SpO2)

    SpO2 is measured by pulse oximetry, the unit is Percent. The unit % is the percentage of oxygen attached hemoglobin relative to the total hemoglobin.

    Time frame: Baseline

  43. Cardiopulmonary Parameters Post 6-week Treatment: SpO2

    SpO2 is measured by pulse oximetry, the unit is Percent. The unit % is the percentage of oxygen attached hemoglobin relative to the total hemoglobin.

    Time frame: 6-week post treatment

07

Results

Posted Jan 11, 2012

Participant flow

Participant flow — Overall Study
MilestoneTicagrelorClopidogrelPlacebo
Started575412
Completed525111
Not completed531
Withdrew: Adverse event401
Withdrew: Incorrect enrolment110
Withdrew: Severe non-compliance to protocol010
Withdrew: Prior commitment medication010

Outcome measures

PrimaryFinal Extent Inhibition of Platelet Aggregation (IPA) Induced by 20 µM Adenosine Diphosphate (ADP) at 2 Hours After First Dose

IPA(%)=(PAb-PAt)/PAb\*100.The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

Time frame:
At 2 hours after first dose of study drug
Reported as:
Median · Percentage
Final Extent Inhibition of Platelet Aggregation (IPA) Induced by 20 µM Adenosine Diphosphate (ADP) at 2 Hours After First Dose
PercentageTicagrelorClopidogrel
Final Extent Inhibition of Platelet Aggregation (IPA) Induced by 20 µM Adenosine Diphosphate (ADP) at 2 Hours After First Dose93.15 (80.4 to 100.0)31.05 (10.3 to 56.9)
PrimarySlope of Extent IPA Offset Curve 4 to 72 Hours After Last Dose of Study Drug

IPA(%)=(PAb-PAt)/PAb\*100.The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition. The unit for the slope of IPA curve is percent/hour.

Time frame:
4 to 72 Hours after last dose of study drug
Reported as:
Least squares mean · Percentage/Hour
Slope of Extent IPA Offset Curve 4 to 72 Hours After Last Dose of Study Drug
Percentage/HourTicagrelorClopidogrel
Slope of Extent IPA Offset Curve 4 to 72 Hours After Last Dose of Study Drug-1.037 ± 0.076-0.482 ± 0.055
SecondaryFinal Extent IPA Induced by 20 µM ADP at 0.5 Hours After First Dose

IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

Time frame:
0.5 hours after first dose
Reported as:
Median · Percentage
Final Extent IPA Induced by 20 µM ADP at 0.5 Hours After First Dose
PercentageTicagrelorClopidogrel
Final Extent IPA Induced by 20 µM ADP at 0.5 Hours After First Dose45.39 (3.0 to 66.4)4.71 (0.0 to 14.8)
SecondaryFinal Extent IPA Induced by 20 µM ADP at 1 Hour After First Dose

IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

Time frame:
1 hour after first dose
Reported as:
Median · Percentage
Final Extent IPA Induced by 20 µM ADP at 1 Hour After First Dose
PercentageTicagrelorClopidogrel
Final Extent IPA Induced by 20 µM ADP at 1 Hour After First Dose86.71 (72.6 to 99.4)15.83 (0.0 to 32.5)
SecondaryFinal Extent IPA Induced by 20 µM ADP at 4 Hours After First Dose

IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

Time frame:
4 hours after first dose
Reported as:
Median · Percentage
Final Extent IPA Induced by 20 µM ADP at 4 Hours After First Dose
PercentageTicagrelorClopidogrel
Final Extent IPA Induced by 20 µM ADP at 4 Hours After First Dose98.39 (84.2 to 100.0)40.87 (16.6 to 69.3)
SecondaryFinal Extent IPA Induced by 20 µM ADP at 8 Hours After First Dose

IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

Time frame:
8 hours after first dose
Reported as:
Median · Percentage
Final Extent IPA Induced by 20 µM ADP at 8 Hours After First Dose
PercentageTicagrelorClopidogrel
Final Extent IPA Induced by 20 µM ADP at 8 Hours After First Dose96.99 (81.1 to 100.0)46.90 (20.4 to 80.8)
SecondaryFinal Extent IPA Induced by 20 µM ADP at 24 Hours After First Dose

IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

Time frame:
24 hours after first dose
Reported as:
Median · Percentage
Final Extent IPA Induced by 20 µM ADP at 24 Hours After First Dose
PercentageTicagrelorClopidogrel
Final Extent IPA Induced by 20 µM ADP at 24 Hours After First Dose87.29 (62.9 to 98.4)49.64 (17.7 to 76.9)
SecondaryFinal Extent IPA Induced by 20 µM ADP at 0 Hour Before Last Dose

IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

Time frame:
0 hour before last dose
Reported as:
Median · Percentage
Final Extent IPA Induced by 20 µM ADP at 0 Hour Before Last Dose
PercentageTicagrelorClopidogrel
Final Extent IPA Induced by 20 µM ADP at 0 Hour Before Last Dose74.53 (56.5 to 98.3)51.75 (32.8 to 66.4)
SecondaryFinal Extent IPA Induced by 20 µM ADP at 2 Hours After Last Dose

IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

Time frame:
2 hours after last dose
Reported as:
Median · Percentage
Final Extent IPA Induced by 20 µM ADP at 2 Hours After Last Dose
PercentageTicagrelorClopidogrel
Final Extent IPA Induced by 20 µM ADP at 2 Hours After Last Dose91.49 (83.0 to 100.0)62.96 (35.2 to 78.8)
SecondaryFinal Extent IPA Induced by 20 µM ADP at 4 Hours After Last Dose

IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

Time frame:
4 hours after last dose
Reported as:
Median · Percentage
Final Extent IPA Induced by 20 µM ADP at 4 Hours After Last Dose
PercentageTicagrelorClopidogrel
Final Extent IPA Induced by 20 µM ADP at 4 Hours After Last Dose96.10 (80.4 to 100.0)61.80 (35.2 to 88.4)
SecondaryFinal Extent IPA Induced by 20 µM ADP at 8 Hours After Last Dose

IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

Time frame:
8 hours after last dose
Reported as:
Median · Percentage
Final Extent IPA Induced by 20 µM ADP at 8 Hours After Last Dose
PercentageTicagrelorClopidogrel
Final Extent IPA Induced by 20 µM ADP at 8 Hours After Last Dose88.31 (77.3 to 100.0)61.31 (39.0 to 61.31)
SecondaryFinal Extent IPA Induced by 20 µM ADP at 24 Hours After Last Dose

IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

Time frame:
24 hours after last dose
Reported as:
Median · Percentage
Final Extent IPA Induced by 20 µM ADP at 24 Hours After Last Dose
PercentageTicagrelorClopidogrel
Final Extent IPA Induced by 20 µM ADP at 24 Hours After Last Dose55.18 (39.1 to 85.4)53.91 (35.1 to 73.3)
SecondaryFinal Extent IPA Induced by 20 µM ADP at 48 Hours After Last Dose

IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

Time frame:
48 hours after last dose
Reported as:
Median · Percentage
Final Extent IPA Induced by 20 µM ADP at 48 Hours After Last Dose
PercentageTicagrelorClopidogrel
Final Extent IPA Induced by 20 µM ADP at 48 Hours After Last Dose30.94 (14.3 to 51.5)45.79 (19.4 to 54.7)
SecondaryFinal Extent IPA Induced by 20 µM ADP at 72 Hours After Last Dose

IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

Time frame:
72 hours after last dose
Reported as:
Median · Percentage
Final Extent IPA Induced by 20 µM ADP at 72 Hours After Last Dose
PercentageTicagrelorClopidogrel
Final Extent IPA Induced by 20 µM ADP at 72 Hours After Last Dose11.76 (0.0 to 34.5)21.09 (10.2 to 47.6)
SecondaryFinal Extent IPA Induced by 20 µM ADP at 120 Hours - Day 5 After Last Dose

IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

Time frame:
120 hours - Day 5 after last dose
Reported as:
Median · Percentage
Final Extent IPA Induced by 20 µM ADP at 120 Hours - Day 5 After Last Dose
PercentageTicagrelorClopidogrel
Final Extent IPA Induced by 20 µM ADP at 120 Hours - Day 5 After Last Dose0.0 (0.0 to 15.2)21.15 (0.0 to 34.7)
SecondaryFinal Extent IPA Induced by 20 µM ADP at 168 Hours - Day 7 After Last Dose

IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference of baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

Time frame:
168 hours - Day 7 after last dose
Reported as:
Median · Percentage
Final Extent IPA Induced by 20 µM ADP at 168 Hours - Day 7 After Last Dose
PercentageTicagrelorClopidogrel
Final Extent IPA Induced by 20 µM ADP at 168 Hours - Day 7 After Last Dose0.0 (0.0 to 11.7)6.32 (0.0 to 22.4)
SecondaryFinal Extent IPA Induced by 20 µM ADP at 240 Hours - Day 10 After Last Dose

IPA(%)=(PAb-PAt)/PAb\*100. The unit % is the percentage of difference for baseline versus post baseline value relative to baseline value of platelet aggregation. PA (platelet aggregation) is measured by LTA (Light Transmittance Aggregometry). PAb is the response at baseline (last measurement before study drug) and PAt is a response at post-treatment. IPA=0% means no PA inhibition and 100% means 100% PA inhibition.

Time frame:
240 hours - Day 10 after last dose
Reported as:
Median · Percentage
Final Extent IPA Induced by 20 µM ADP at 240 Hours - Day 10 After Last Dose
PercentageTicagrelorClopidogrel
Final Extent IPA Induced by 20 µM ADP at 240 Hours - Day 10 After Last Dose1.64 (0.0 to 9.9)0.98 (0.0 to 13.8)
SecondaryCardiopulmonary Parameters at Baseline: Forced Expiratory Volume in 1 Second (FEV1)

FEV1 is measured by Spirometry, the unit is Liter.

Time frame:
Baseline
Reported as:
Mean · Liter
Cardiopulmonary Parameters at Baseline: Forced Expiratory Volume in 1 Second (FEV1)
LiterTicagrelorClopidogrelPlacebo
Cardiopulmonary Parameters at Baseline: Forced Expiratory Volume in 1 Second (FEV1)2.79 ± 0.7252.71 ± 0.7912.94 ± 0.654
SecondaryCardiopulmonary Parameters at Post 6-week Treatment: FEV1

FEV1 is measured by Spirometry, the unit is Liter.

Time frame:
6-week post treatment
Reported as:
Mean · Liter
Cardiopulmonary Parameters at Post 6-week Treatment: FEV1
LiterTicagrelorClopidogrelPlacebo
Cardiopulmonary Parameters at Post 6-week Treatment: FEV12.77 ± 0.7122.74 ± 0.7512.95 ± 0.727
SecondaryCardiopulmonary Parameters at Baseline: Forced Vital Capacity (FVC)

FVC is measured by Spirometry, the unit is Liter.

Time frame:
Baseline
Reported as:
Mean · Liter
Cardiopulmonary Parameters at Baseline: Forced Vital Capacity (FVC)
LiterTicagrelorClopidogrelPlacebo
Cardiopulmonary Parameters at Baseline: Forced Vital Capacity (FVC)3.72 ± 0.9033.73 ± 1.0824.03 ± 0.858
SecondaryCardiopulmonary Parameters at Post 6-week Treatment: FVC

FVC is measured by Spirometry, the unit is Liter.

Time frame:
6-week post treatment
Reported as:
Mean · Liter
Cardiopulmonary Parameters at Post 6-week Treatment: FVC
LiterTicagrelorClopidogrelPlacebo
Cardiopulmonary Parameters at Post 6-week Treatment: FVC3.70 ± 0.9333.78 ± 1.0293.98 ± 0.890
SecondaryCardiopulmonary Parameters at Baseline: Ratio of Forced Expiratory Volume in 1 Second Over Forced Vital Capacity (FEV1/FVC Ratio)

FEV1/FVC Ratio is measured by Spirometry, the unit is Ratio.

Time frame:
Baseline
Reported as:
Mean · Ratio
Cardiopulmonary Parameters at Baseline: Ratio of Forced Expiratory Volume in 1 Second Over Forced Vital Capacity (FEV1/FVC Ratio)
RatioTicagrelorClopidogrelPlacebo
Cardiopulmonary Parameters at Baseline: Ratio of Forced Expiratory Volume in 1 Second Over Forced Vital Capacity (FEV1/FVC Ratio)75.01 ± 7.04973.04 ± 6.76473.13 ± 7.226
SecondaryCardiopulmonary Parameters at Post 6-week Treatment: FEV1/FVC Ratio

FEV1/FVC Ratio is measured by Spirometry, the unit is Ratio.

Time frame:
6-week post treatment
Reported as:
Mean · Ratio
Cardiopulmonary Parameters at Post 6-week Treatment: FEV1/FVC Ratio
RatioTicagrelorClopidogrelPlacebo
Cardiopulmonary Parameters at Post 6-week Treatment: FEV1/FVC Ratio74.71 ± 5.69472.84 ± 6.37174.27 ± 7.836
SecondaryCardiopulmonary Parameters at Baseline: Mean Forced Expiratory Flow Between 25% and 75% of the FVC (FEF25-75)

FEF25-75 is measured by Spirometry, the unit is Liter/Second.

Time frame:
Baseline
Reported as:
Mean · Liter/second
Cardiopulmonary Parameters at Baseline: Mean Forced Expiratory Flow Between 25% and 75% of the FVC (FEF25-75)
Liter/secondTicagrelorClopidogrelPlacebo
Cardiopulmonary Parameters at Baseline: Mean Forced Expiratory Flow Between 25% and 75% of the FVC (FEF25-75)2.88 ± 1.2512.70 ± 1.2082.50 ± 1.243
SecondaryCardiopulmonary Parameters Post 6-week Treatment: FEF25-75

FEF25-75 is measured by Spirometry, the unit is Liter/Second.

Time frame:
6-week post treatment
Reported as:
Mean · Liter/second
Cardiopulmonary Parameters Post 6-week Treatment: FEF25-75
Liter/secondTicagrelorClopidogrelPlacebo
Cardiopulmonary Parameters Post 6-week Treatment: FEF25-752.77 ± 1.2892.67 ± 1.1562.91 ± 1.375
SecondaryCardiopulmonary Parameters at Baseline: Functional Residual Capacity (FRC)

FRC is measured by Body Box Plethysmography, the unit is Liter.

Time frame:
Baseline
Reported as:
Mean · Liter
Cardiopulmonary Parameters at Baseline: Functional Residual Capacity (FRC)
LiterTicagrelorClopidogrelPlacebo
Cardiopulmonary Parameters at Baseline: Functional Residual Capacity (FRC)2.79 ± 0.8272.89 ± 0.8762.91 ± 0.679
SecondaryCardiopulmonary Parameters Post 6-week Treatment: FRC

FRC is measured by Body Box Plethysmography, the unit is Liter.

Time frame:
6-week post treatment
Reported as:
Mean · Liter
Cardiopulmonary Parameters Post 6-week Treatment: FRC
LiterTicagrelorClopidogrelPlacebo
Cardiopulmonary Parameters Post 6-week Treatment: FRC2.73 ± 0.7232.79 ± 0.8572.75 ± 1.000
SecondaryCardiopulmonary Parameters at Baseline: Total Lung Capacity (TLC)

TLC is measured by Body Box Plethysmography, the unit is Liter.

Time frame:
Baseline
Reported as:
Mean · Liter
Cardiopulmonary Parameters at Baseline: Total Lung Capacity (TLC)
LiterTicagrelorClopidogrelPlacebo
Cardiopulmonary Parameters at Baseline: Total Lung Capacity (TLC)5.78 ± 1.2995.83 ± 1.4016.10 ± 1.037
SecondaryCardiopulmonary Parameters Post 6-week Treatment: TLC

TLC is measured by Body Box Plethysmography, the unit is Liter.

Time frame:
6-week post treatment
Reported as:
Mean · Liter
Cardiopulmonary Parameters Post 6-week Treatment: TLC
LiterTicagrelorClopidogrelPlacebo
Cardiopulmonary Parameters Post 6-week Treatment: TLC5.70 ± 1.1825.85 ± 1.3965.96 ± 1.422
SecondaryCardiopulmonary Parameters at Baseline: Residual Volume (RV)

RV is measured by Body Box Plethysmography, the unit is Liter.

Time frame:
Baseline
Reported as:
Mean · Liter
Cardiopulmonary Parameters at Baseline: Residual Volume (RV)
LiterTicagrelorClopidogrelPlacebo
Cardiopulmonary Parameters at Baseline: Residual Volume (RV)1.94 ± 0.7802.01 ± 0.6431.91 ± 0.363
SecondaryCardiopulmonary Parameters Post 6-week Treatment: RV

RV is measured by Body Box Plethysmography, the unit is Liter.

Time frame:
6-week post treatment
Reported as:
Mean · Liter
Cardiopulmonary Parameters Post 6-week Treatment: RV
LiterTicagrelorClopidogrelPlacebo
Cardiopulmonary Parameters Post 6-week Treatment: RV1.88 ± 0.6211.97 ± 0.5591.90 ± 0.751
SecondaryCardiopulmonary Parameters at Baseline: Minute Ventilation (VE)

VE is measured by Spirometry and Body Box Plethysmography, the unit is Liter/Minute

Time frame:
Baseline
Reported as:
Mean · Liter/minute
Cardiopulmonary Parameters at Baseline: Minute Ventilation (VE)
Liter/minuteTicagrelorClopidogrelPlacebo
Cardiopulmonary Parameters at Baseline: Minute Ventilation (VE)12.92 ± 3.95012.17 ± 3.55212.06 ± 4.054
SecondaryCardiopulmonary Parameters Post 6-week Treatment: VE

VE is measured by Spirometry and Body Box Plethysmography, the unit is Liter/Minute

Time frame:
6-week post treatment
Reported as:
Mean · Liter/minute
Cardiopulmonary Parameters Post 6-week Treatment: VE
Liter/minuteTicagrelorClopidogrelPlacebo
Cardiopulmonary Parameters Post 6-week Treatment: VE13.69 ± 3.58213.14 ± 5.51511.45 ± 3.540
SecondaryCardiopulmonary Parameters at Baseline: Respiratory Rate (RR)

RR is measured by Spirometry and Body Box Plethysmography, the unit is Breaths/Minute.

Time frame:
Baseline
Reported as:
Mean · Breaths/minute
Cardiopulmonary Parameters at Baseline: Respiratory Rate (RR)
Breaths/minuteTicagrelorClopidogrelPlacebo
Cardiopulmonary Parameters at Baseline: Respiratory Rate (RR)14.79 ± 2.43314.15 ± 2.74315.5 ± 1.977
SecondaryCardiopulmonary Parameters Post 6-week Treatment: RR

RR is measured by Spirometry and Body Box Plethysmography, the unit is Breaths/Minute.

Time frame:
6-week post treatment
Reported as:
Mean · Breaths/minute
Cardiopulmonary Parameters Post 6-week Treatment: RR
Breaths/minuteTicagrelorClopidogrelPlacebo
Cardiopulmonary Parameters Post 6-week Treatment: RR15.21 ± 2.81715.10 ± 2.30314.91 ± 0.944
SecondaryCardiopulmonary Parameters at Baseline: Tidal Volume (VT)

VT is measured by Body Box Plethysmography, the unit is Liter/Minute.

Time frame:
Baseline
Reported as:
Mean · Liters/minute
Cardiopulmonary Parameters at Baseline: Tidal Volume (VT)
Liters/minuteTicagrelorClopidogrelPlacebo
Cardiopulmonary Parameters at Baseline: Tidal Volume (VT)0.96 ± 0.3260.89 ± 0.3220.89 ± 0.273
SecondaryCardiopulmonary Parameters Post 6-week Treatment: VT

VT is measured by Body Box Plethysmography, the unit is Liter/Minute.

Time frame:
6-week post treatment
Reported as:
Mean · Liters/minute
Cardiopulmonary Parameters Post 6-week Treatment: VT
Liters/minuteTicagrelorClopidogrelPlacebo
Cardiopulmonary Parameters Post 6-week Treatment: VT0.92 ± 0.2640.93 ± 0.3930.83 ± 0.329
SecondaryCardiopulmonary Parameters at Baseline: Single Breath Diffusing Capacity for the Lungs Using Carbon Monoxide (DLCOSB)

DLCOSB is measured by Body Box Plethysmography, the unit is Percent.

Time frame:
Baseline
Reported as:
Mean · Percent
Cardiopulmonary Parameters at Baseline: Single Breath Diffusing Capacity for the Lungs Using Carbon Monoxide (DLCOSB)
PercentTicagrelorClopidogrelPlacebo
Cardiopulmonary Parameters at Baseline: Single Breath Diffusing Capacity for the Lungs Using Carbon Monoxide (DLCOSB)17.00 ± 8.67317.29 ± 10.89115.83 ± 6.013
SecondaryCardiopulmonary Parameters Post 6-week Treatment: DLCOSB

DLCOSB is measured by Body Box Plethysmography, the unit is Percent.

Time frame:
6-week post treatment
Reported as:
Mean · Percent
Cardiopulmonary Parameters Post 6-week Treatment: DLCOSB
PercentTicagrelorClopidogrelPlacebo
Cardiopulmonary Parameters Post 6-week Treatment: DLCOSB16.38 ± 8.09016.53 ± 8.28616.09 ± 7.190
SecondaryCardiopulmonary Parameters at Baseline: Ejection Fraction (EF)

EF is measured by Echocardiogram, the unit is Percent. The ejection fraction is defined by: (LV diastolic volume - LV systolic volume)/LV diastolic volume. The unit % is the percentage change of left ventricular diastolic versus systolic volume relative to the diastolic volume. LV is the left ventricle.

Time frame:
Baseline
Reported as:
Mean · Percent
Cardiopulmonary Parameters at Baseline: Ejection Fraction (EF)
PercentTicagrelorClopidogrelPlacebo
Cardiopulmonary Parameters at Baseline: Ejection Fraction (EF)57.96 ± 9.30261.91 ± 7.62459.92 ± 10.013
SecondaryCardiopulmonary Parameters Post 6-week Treatment: EF

EF is measured by Echocardiogram, the unit is Percent. The ejection fraction is defined by: (LV diastolic volume - LV systolic volume)/LV diastolic volume. The unit % is the percentage change of left ventricular diastolic versus systolic volume relative to the diastolic volume. LV is the left ventricle.

Time frame:
6-week post treatment
Reported as:
Mean · Percent
Cardiopulmonary Parameters Post 6-week Treatment: EF
PercentTicagrelorClopidogrelPlacebo
Cardiopulmonary Parameters Post 6-week Treatment: EF60.70 ± 8.43062.38 ± 7.09660.73 ± 9.665
SecondaryCardiopulmonary Parameters at Baseline: N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)

NT-proBNP is measured by clinical lab, the unit is pg/mL.

Time frame:
Baseline
Reported as:
Mean · pg/ml
Cardiopulmonary Parameters at Baseline: N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
pg/mlTicagrelorClopidogrelPlacebo
Cardiopulmonary Parameters at Baseline: N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)163.34 ± 184.298185.98 ± 227.141145.41 ± 144.522
SecondaryCardiopulmonary Parameters Post 6-week Treatment: NT-proBNP

NT-proBNP is measured by clinical lab, the unit is pg/mL.

Time frame:
6-week post treatment
Reported as:
Mean · pg/ml
Cardiopulmonary Parameters Post 6-week Treatment: NT-proBNP
pg/mlTicagrelorClopidogrelPlacebo
Cardiopulmonary Parameters Post 6-week Treatment: NT-proBNP139.88 ± 170.347214.43 ± 313.429140.68 ± 145.003
SecondaryCardiopulmonary Parameters at Baseline: Blood Oxygen Saturation Measured by Pulse Oximetry (SpO2)

SpO2 is measured by pulse oximetry, the unit is Percent. The unit % is the percentage of oxygen attached hemoglobin relative to the total hemoglobin.

Time frame:
Baseline
Reported as:
Mean · Percent
Cardiopulmonary Parameters at Baseline: Blood Oxygen Saturation Measured by Pulse Oximetry (SpO2)
PercentTicagrelorClopidogrelPlacebo
Cardiopulmonary Parameters at Baseline: Blood Oxygen Saturation Measured by Pulse Oximetry (SpO2)96.59 ± 1.57096.78 ± 1.94997.58 ± 1.240
SecondaryCardiopulmonary Parameters Post 6-week Treatment: SpO2

SpO2 is measured by pulse oximetry, the unit is Percent. The unit % is the percentage of oxygen attached hemoglobin relative to the total hemoglobin.

Time frame:
6-week post treatment
Reported as:
Mean · Percentage
Cardiopulmonary Parameters Post 6-week Treatment: SpO2
PercentageTicagrelorClopidogrelPlacebo
Cardiopulmonary Parameters Post 6-week Treatment: SpO297.73 ± 1.23997.35 ± 1.26298.56 ± 1.014

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ticagrelor—0/57 (0%)36/57 (63.2%)
Clopidogrel—0/54 (0%)22/54 (40.7%)
Placebo—0/12 (0%)7/12 (58.3%)
Most frequent other events
Showing 10 of 23
Most frequent other events
EventTicagrelorClopidogrelPlacebo
DyspnoeaRespiratory, thoracic and mediastinal disorders20/576/540/12
Increased Tendency To BruiseSkin and subcutaneous tissue disorders9/572/540/12
ContusionInjury, poisoning and procedural complications6/573/540/12
Vessel Puncture Site HaematomaGeneral disorders3/575/541/12
Visual ImpairmentEye disorders0/570/541/12
DyspepsiaGastrointestinal disorders2/570/541/12
Abdominal Wall HaematomaGastrointestinal disorders0/570/541/12
FatigueGeneral disorders4/572/541/12
Chest DiscomfortGeneral disorders1/570/541/12
CellulitisInfections and infestations0/570/541/12

Baseline characteristics

Age Continuous
Age Continuous(Year)TicagrelorClopidogrelPlaceboTotal
Mean62.2 ± 9.1065.4 ± 7.9863.9 ± 8.3263.8 ± 8.62
Sex: Female, Male
Sex: Female, Male(Participants)TicagrelorClopidogrelPlaceboTotal
Female1414230
Male43401093
08

Study locations

9 sites
  • Research Site
    Baton Rouge, Louisiana, United States
  • Research Site
    Baltimore, Maryland, United States
  • Research Site
    Towson, Maryland, United States
  • Research Site
    Cincinnati, Ohio, United States
  • Research Site
    Oklahoma City, Oklahoma, United States
  • Research Site
    Philadelphia, Pennsylvania, United States
  • Research Site
    Rapid City, South Dakota, United States
  • Research Site
    Houston, Texas, United States
  • Research Site
    Sheffield, United Kingdom
09

References and documents

Publications

  • Jeong YH, Bliden KP, Antonino MJ, Park KS, Tantry US, Gurbel PA. Usefulness of the VerifyNow P2Y12 assay to evaluate the antiplatelet effects of ticagrelor and clopidogrel therapies. Am Heart J. 2012 Jul;164(1):35-42. doi: 10.1016/j.ahj.2012.03.022. Epub 2012 Jun 13. PubMed 22795280 ↗
  • Jeong YH, Bliden KP, Tantry US, Gurbel PA. High on-treatment platelet reactivity assessed by various platelet function tests: is the consensus-defined cut-off of VASP-P platelet reactivity index too low? J Thromb Haemost. 2012 Mar;10(3):487-9. doi: 10.1111/j.1538-7836.2011.04604.x. No abstract available. PubMed 22212857 ↗
  • Tantry US, Bliden KP, Wei C, Storey RF, Armstrong M, Butler K, Gurbel PA. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies. Circ Cardiovasc Genet. 2010 Dec;3(6):556-66. doi: 10.1161/CIRCGENETICS.110.958561. Epub 2010 Nov 15. PubMed 21079055 ↗
  • Storey RF, Bliden KP, Patil SB, Karunakaran A, Ecob R, Butler K, Teng R, Wei C, Tantry US, Gurbel PA; ONSET/OFFSET Investigators. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. J Am Coll Cardiol. 2010 Jul 13;56(3):185-93. doi: 10.1016/j.jacc.2010.01.062. PubMed 20620737 ↗
  • Gurbel PA, Bliden KP, Butler K, Tantry US, Gesheff T, Wei C, Teng R, Antonino MJ, Patil SB, Karunakaran A, Kereiakes DJ, Parris C, Purdy D, Wilson V, Ledley GS, Storey RF. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009 Dec 22;120(25):2577-85. doi: 10.1161/CIRCULATIONAHA.109.912550. Epub 2009 Nov 18. PubMed 19923168 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2012, 2 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2007
First posted
Sep 12, 2007
Start
Oct 2007
Primary completionActual
Mar 2009
CompletionActual
Mar 2009
Results first posted
Jan 11, 2012
Last update
Jan 13, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 13, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00528411
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 12, 2007
Start date
Oct 2007
Primary completion
Mar 2009
Completion
Mar 2009
Results posted
Jan 11, 2012
Last update
Jan 13, 2012

Study contacts

Philip Sager, MD
study director · AstraZeneca
Paul Gurbel, MD
principal investigator · Platelet & Thrombosis Research, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ticagrelor

Start the discussion